Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. (KTTA) is a United States-based biopharmaceutical company trading on the NASDAQ exchange. The company focuses on the research, development, and commercialization of novel treatments for central nervous system (CNS) disorders. Pasithea is dedicated to addressing unmet medical needs in areas such as psychiatric and neurological conditions. Through innovative drug development programs, the company aims to improve the lives of patients suffering from debilitating mental health issues. Pasithea's activities include preclinical and clinical studies, formulation development, and exploring strategic partnerships to accelerate the availability of its therapeutic candidates. The company operates within the broader healthcare and biotechnology sector, seeking to contribute to advancements in CNS disorder treatments.